Henlix Biotech Inc., an innovative biopharmaceutical company, was co-founded by two American biopharmaceutical veterans, Dr. Scott Liu and Dr. Weidong Jiang in October 2010, in Taiwan and expanded its research site in the San Francisco Bay Area. The company specializes in the discovery and development of innovative monoclonal antibody therapeutics, bi-specific antibodies and antibody drug conjugates (ADCs) by using state of the art technologies. With its core mission in making quality antibody-based therapeutics available and affordable to all patients in need worldwide, Henlix aims to become a trusted leading international biopharmaceutical company with a significant global impact.


Efficient R&D Independent innovation People-oriented

To date, Henlix has 6 innovative antibody-based therapeutics candidates in the pipeline; the lead product has entered a Phase I clinical trial in 2016. The company targets to file at least 1 IND per year. Henlix has established a state of the art antibody discovery and development engine to accelerate multiple promising novel antibody candidates to the clinic in a cost-effective manner. Henlix emphasizes on teamwork, cares for the growth and development of each employee, endeavors to construct a fair and just, as well as positive working environment, so as to create a productive work environment for the employees' career growth.



Scott Liu Scott Liu Ph.D. Co-founder / Chief Executive Officer
  • Ph.D. / Department of Biology, Purdue University
  • postdoctoral fellow / Stanford University
  • iMBA courses / Syracuse University
  • Vice President / UBI
  • QC Director / Bristol-Myers Squibb and Amgen
Weidong Jiang Weidong Jiang Ph.D. President / Chief Scientific Officer
  • MS / Chinese Academy of Sciences
  • Ph.D. / University of Giessen, Germany
  • Post-doctoral / University of California
  • Senior scientist and directors / ChemGenics (Millennium), Microcide, Applied Mol, Evolution (Eli Lilly), Vasgene, and Catalyst Biosciences
EUGENE LIU EUGENE LIU Ph.D. VP / Chief Medical Officer
  • M.D. / Taipei Medical College
  • Ph.D. / University of Minnesota
  • Chief Resident of Hemato-oncology / Taipei Municipal Jen-Ai Hospital
  • Clinical Fellow / Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota
  • Associate Professor / Graduate Institute of Clinical Medicine, Taipei Medical University
  • Attending doctor / Division of Hematology and Oncology Department of Medicine, Wanfang Hospital, Taipei Medical University
BRUCE HO BRUCE HO VP / Chief Financial Officer
  • MBA / Grand Canyon University (Phoenix)
  • CIO / Industrial Bank of Taiwan Securities Co. Ltd
  • CEO / Group of Investment management business / JihSun Financial Holding company.
  • CSO, CIO / Masterlink Securities Corp.
Wenfeng Xu Wenfeng Xu Ph.D. VP / Product Development
  • Ph.D. in Molecular Biology / Shanghai Institute of Biochemistry, Chinese Academy of Science
  • postdoctoral study at University of Washington in Seattle
  • Principal Scientist / ZymoGenetics Inc.
  • Director / Molecular Immunology / Novo Nordisk Research Center
  • Associate Director / Bioanalytical Science for Cancer Immunotherapy / Genentech


July 2018

HLX20 (PD-L1) has been approval to conduct first in human trial clinical study by China Food and Drug Administration.

June 2018

Henlix Biotech Co.,Ltd. is a 100% wholly-owned subsidiary of Shanghai Henlius Biotech, Inc.

October 2017

HLX10 has been approval to conduct first in human trial clinical study by Taiwan, US and China Food and Drug Administration.

October 2017

The Capital of Henlix Biotech Co., Ltd. is 0.78 Billions NTD.

September 2017


December 2016

Henlix Biotech Co., Ltd. has been awarded the 13th National Innovation Award for Development and Application of an Innovative Monoclonal Antibody HLX07 for Cancer Therapy in the Pharmaceutical and New Medical Technology Category by the Institute for Biotechnology and Medicine Industry.

June 2016

HLX07 Investigational New Drug Application (IND) was approved by Taiwan, US and Chinese Food and Drug Administration, Phase I trial was started in August 2016.

January 2016

In January 2016, Henlix completed financing of 258,000,000 NT dollars, with the actual receipt capital of 663,000,000 NT dollars.

June 2015

In June 2015, Henlix's authorized capital was 100,000,000 NT dollars, with actual receipt capital of 404,000,000 NT dollars.

November 2014

In November 2014, Henlix completed financing of 240,000,000 NT dollars, under 96.4% of holdings, by U.S. Henlix.

July 2014

In July 2014, Henlix positioned its research and development focus on innovative monoclonal antibody development.

April 2014

In April 2014, Henlix Biotech Inc. was restructured into Henlix Biotech Ltd.

March 2013

In March 2013, Henlix completed financing of 8,780,000 NT dollars, with actual receipt capital of 8,880,000 NT dollars.

January 2012

In 2012, Henlix started to provide R&D service of innovative monoclonal antibody for U.S Henlix and Shanghai Henlius

March 2011

In 2011, Henlix cooperated with the Industry-Academy Cooperation Incubation Center of the Taipei Medical College to conduct the research project of innovative monoclonal antibodies.

October 2010

In October 2010, the Henlix Biotech Inc.was founded in Taiwan.